New AAP Guidance: Exome and genome sequencing recommended as first-line tests. Learn more
Board Member
Thomas Fuchs, Dr.sc., has served on the Board of Directors at GeneDx since September 2025.
As the SVP and Chief AI Officer at Eli Lilly, Dr. Fuchs provides vision, strategic direction, and overall leadership of AI initiatives for drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He also identifies, builds and manages AI and machine learning solutions to help Lilly deliver medicines to patients around the world. Before joining Lilly, he was the Dean and inaugural Department Chair for AI and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy Professor for AI and Computational Pathology at the Icahn School of Medicine at Mount Sinai. Prior to Mount Sinai Dr. Fuchs held positions at Memorial Sloan Kettering Cancer Center, NASA’s Jet Propulsion Laboratory and the California Institute of Technology and founded three companies, including Paige AI. Dr. Fuchs holds a doctoral degree in machine learning from ETH Zurich and a master’s in technical mathematics from Graz Technical University in Austria.
